SVRA Savara, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 11, 2026
$4,81
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$3,3452 haftanın en düşüğü
$7,0152 haftanın en yükseği
Piyasa Değeri (MRQ)
$988M
P/E
-9.1
Hisse Başına Kâr
$-0.53
rozetleriniz
52 Haftlık Aralık
$3–$7
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$11
P/E
-9.1
ROE
-73.4%
Net Kâr Marjı
·
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
SVRA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$4.81
Piyasa Değeri (MRQ)
$988M
P/E
-9.1
Hisse Başına Kâr
$-0.53
ROE
-73.4%
D/E Borç/Özsermaye (MRQ)
0.2
52 Haftlık Aralık
$3–$7
SVRA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir·2016-12-31 → 2020-12-31
Hisse Başına Kâr$-0.532021-12-31 → 2025-12-31
Serbest Nakit Akışı$-101M2016-12-31 → 2025-12-31
Net kar marjı·2016-12-31 → 2020-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | SVRA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -9.15Y ort. ≈-8.4 | ≈-8.4 | · | · | |
| F/D (MRQ) | 6.95Y ort. ≈3.3 | ≈3.3 | 4.9 | Aşırı değerli | |
| EV / EBITDA | -6.35Y ort. ≈-4.7 | ≈-4.7 | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -8.95Y ort. ≈-8.4 | ≈-8.4 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -9.05Y ort. ≈-8.4 | ≈-8.4 | · | · | |
| EV / FCF (TTM) | -7.65Y ort. ≈-5.6 | ≈-5.6 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 4.95Y ort. ≈3.3 | ≈3.3 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | SVRA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| ROA | -51.0%5Y ort. ≈-35.2% | ≈-35.2% | -21.8% | Zayıf | |
| ROE | -73.4%5Y ort. ≈-43.6% | ≈-43.6% | -15.4% | Zayıf | |
| ROIC | -53.0% | · | -117.8% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | SVRA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.25Y ort. ≈0.2 | ≈0.2 | · | · | |
| Cari Oran (MRQ) | 10.15Y ort. ≈15.2 | ≈15.2 | 10.6 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 11.65Y ort. ≈14.8 | ≈14.8 | 2.5 | Güçlü likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.25Y ort. ≈0.2 | ≈0.2 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Bu oran grubu için henüz veri yok
Bu oran grubunu hesaplamak için henüz yeterli temel veriye sahip değil.
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-5.9%
Sonraki Rapor
Kas 10, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 11, 2026 | $-0.16 | $-0.15 | -10.2% |
| 31 Mart 2026 | May 11, 2026 | $-0.15 | $-0.14 | -9.2% |
| 31 Aralık 2025 | $-0.13 | $-0.12 | -8.2% | |
| 30 Eylül 2025 | $-0.14 | $-0.14 | -3.5% | |
| 30 Haziran 2025 | $-0.14 | $-0.12 | -12.6% | |
| 31 Mart 2025 | $-0.12 | $-0.13 | 8.5% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | $257.0K | $0 | · | $0 | $400.0K | $54.0K | $0 | |
| SG&A Expense | $42M | $25M | $16M | $11M | $12M | $14M | $13M | $11M | $11M | $3M | $2M | $9M | |
| Operating Expenses | $124M | $103M | $60M | $39M | $41M | $50M | $79M | $70M | $30M | $11M | $6M | $29M | |
| Operating Income | $-124M | $-103M | $-60M | $-39M | $-41M | $-49M | $-79M | $-70M | $-30M | $-11M | $-6M | $-29M | |
| Interest Expense | · | · | · | · | · | · | · | · | $1M | $452.0K | $3M | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $122.0K | $130.0K | $69.0K | |
| Other Non-op | $5M | $7M | $5M | $689.0K | $-2M | $-315.0K | $852.0K | $1M | $-3M | $-332.0K | $-3M | $508.0K | |
| Pretax Income | $-119M | $-96M | $-55M | $-38M | $-43M | $-50M | $-78M | $-69M | $-33M | $-11M | $-9M | $-29M | |
| Income Tax | $0 | $9.0K | · | · | · | · | · | $-7M | $-4M | $-357.0K | $0 | $0 | |
| Net Income | $-119M | $-96M | $-55M | $-38M | $-43M | $-50M | $-78M | $-62M | $-30M | $-11M | $-9M | $-29M | |
| EPS (Basic) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | · | · | · | · | · | · | · | |
| Shares (Basic) | 222,387,531 | 198,191,936 | 165,204,652 | 152,771,817 | 133,919,145 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 222,387,531 | 198,191,936 | 165,204,652 | 152,771,817 | 133,919,145 | · | · | · | · | · | · | · | |
| EBITDA | $-124M | · | $-60M | $-39M | $-41M | $-49M | $-78M | $-70M | $-30M | $-36M | $-39M | $-29M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33M | $15M | $27M | $52M | $34M | $23M | $50M | $24M | $22M | $13M | $17M | $13M | |
| Short-term Investments | $203M | $181M | $136M | $74M | $127M | $59M | $72M | $87M | $72M | $0 | · | · | |
| Prepaid Expense | $6M | $6M | $4M | $3M | $4M | $3M | $2M | $3M | $4M | $840.0K | $1M | $1M | |
| Current Assets | $242M | $202M | $166M | $129M | $165M | $85M | $124M | $113M | $98M | $15M | $42M | $58M | |
| PP&E (Net) | $100.0K | $165.0K | $270.0K | $51.0K | $73.0K | $156.0K | $352.0K | $522.0K | $925.0K | $793.0K | $226.0K | $188.0K | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $565.0K | $532.0K | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $851.0K | $504.0K | $339.0K | $344.0K | |
| Goodwill | · | · | · | · | · | $0 | · | $27M | $27M | $3M | $3M | $3M | |
| Other Non-current Assets | $84.0K | $242.0K | $387.0K | $116.0K | $251.0K | $250.0K | $673.0K | $131.0K | $131.0K | $131.0K | $183.0K | $353.0K | |
| Total Assets | $253M | $213M | $178M | $140M | $177M | $98M | $136M | $152M | $160M | $29M | $54M | $70M | |
| Accounts Payable | $6M | $5M | $4M | $1M | $1M | $3M | $3M | $4M | $3M | $536.0K | $3M | $1M | |
| Accrued Liabilities | $15M | $10M | $7M | $5M | $5M | $6M | $5M | $3M | $3M | $2M | $8M | $6M | |
| Current Liabilities | $20M | $15M | $11M | $6M | $15M | $8M | $11M | $7M | $6M | $3M | $23M | $8M | |
| Capital Leases | · | $100.0K | $200.0K | $50.0K | $100.0K | $100.0K | $300.0K | · | $297.0K | $579.0K | $25.0K | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | $7M | $2M | $3M | $3M | |
| Other Non-current Liabilities | $0 | $87.0K | $247.0K | $54.0K | $117.0K | $84.0K | $513.0K | $70.0K | · | · | · | · | |
| Total Liabilities | $50M | $41M | $37M | $32M | $32M | $33M | $35M | $44M | $40M | $21M | $30M | $12M | |
| Long-term Debt | $30M | $27M | $26M | $26M | $26M | $25M | · | · | · | · | · | · | |
| Total Debt | $30M | · | $26M | $26M | $26M | · | · | · | · | · | · | · | |
| Common Stock | $204.0K | $173.0K | $140.0K | $116.0K | $116.0K | $55.0K | $52.0K | $36.0K | $32.0K | $5.0K | $164.0K | $159.0K | |
| Retained Earnings | $-608M | $-489M | $-393M | $-339M | $-301M | $-258M | $-208M | $-130M | $-68M | $-38M | $-275M | $-235M | |
| AOCI | $-87.0K | $-750.0K | $-271.0K | $-605.0K | $5.0K | $942.0K | $-17.0K | $200.0K | $958.0K | $-591.0K | $-17.0K | $-25.0K | |
| Stockholders' Equity | $203M | $171M | $140M | $108M | $144M | $64M | $102M | $108M | $119M | $-36M | $-27M | $-18M | |
| Liabilities + Equity | $253M | $213M | $178M | $140M | $177M | $98M | $136M | $152M | $160M | $29M | $54M | $70M | |
| Shares Outstanding | 204,567,283 | 172,423,223 | 138,143,545 | 114,046,345 | 114,036,892 | 54,152,955 | 50,790,441 | 35,146,096 | 30,509,522 | 3,162,573 | 163,614,297 | 159,458,376 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $87.0K | $130.0K | $77.0K | $31.0K | $136.0K | $255.0K | $1M | $526.0K | · | $99.0K | $146.0K | $85.0K | |
| Stock-based Comp | $14M | $10M | $4M | $2M | $3M | $5M | $4M | $4M | $552.0K | $209.0K | $153.0K | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $-7M | $-3M | $-2M | · | · | |
| Other Non-cash | · | · | · | · | · | · | $28M | · | · | · | · | · | |
| Operating Cash Flow | $-101M | $-89M | $-51M | $-35M | $-40M | $-40M | $-45M | $-39M | $-28M | $-8M | $-5M | $-25M | |
| CapEx | $22.0K | $25.0K | $296.0K | $9.0K | $57.0K | $47.0K | $148.0K | $141.0K | $495.0K | $8.0K | $165.0K | $147.0K | |
| Investing Cash Flow | $-18M | $-40M | $-57M | $53M | $-69M | $9M | $16M | $-14M | $-69M | · | · | · | |
| Debt Issued | $30M | · | · | $26M | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $2M | · | · | $88.0K | · | · | · | · | $-4M | · | · | · | |
| Stock Issued | · | · | · | · | · | $2M | $30M | $505.0K | $2M | $20M | $2M | $30M | |
| Net Stock Activity | · | · | · | · | · | $2M | $30M | $505.0K | $2M | $20M | $2M | $30M | |
| Financing Cash Flow | $138M | $118M | $83M | $87.0K | $121M | $4M | $55M | $55M | $106M | · | · | · | |
| Net Change in Cash | $18M | $-11M | $-26M | $18M | $11M | $-27M | $26M | $2M | $9M | $-3M | $4M | $10M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-101M | · | $-51M | $-35M | $-40M | $-40M | $-45M | $-39M | $-29M | $-37M | $-33M | $-25M | |
| Levered FCF | · | · | · | · | · | · | · | · | $-30M | $-39M | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -19182.9% | · | · | · | -28481.2% | · | · | |
| Net Margin | · | · | · | · | · | -19305.5% | · | · | · | -28203.1% | · | · | |
| Pretax Margin | · | · | · | · | · | -19305.5% | · | · | · | -30085.2% | · | · | |
| EBITDA Margin | · | · | · | · | · | -19182.9% | · | · | · | -28481.2% | · | · | |
| ROA | -51.0% | · | -34.5% | -24.1% | -31.4% | -42.4% | -54.2% | -39.4% | -31.6% | -100.1% | -63.9% | -45.6% | |
| ROE | -73.4% | · | -38.1% | -34.0% | -28.7% | -70.4% | -75.0% | -54.4% | -71.4% | 410.9% | -1425.5% | -53.9% | |
| ROIC | -53.0% | · | · | · | · | · | · | -56.9% | -22.4% | -350.2% | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.8 | · | 15.7 | 22.0 | 11.3 | 10.4 | 11.4 | 15.6 | 16.3 | 2.5 | 1.8 | 6.9 | |
| Quick Ratio | 11.6 | · | 15.3 | 21.5 | 11.0 | 10.1 | 11.2 | 15.3 | 15.7 | 1.8 | 1.0 | 4.2 | |
| Debt / Equity | 0.1 | · | 0.2 | 0.2 | 0.2 | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | · | 0.2 | 0.2 | 0.1 | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | -25.8 | -17.1 | -65.3 | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.99 | · | $1.02 | $0.94 | $1.27 | $1.19 | $2.00 | $3.08 | $3.91 | $0.04 | $0.15 | $0.37 | |
| Cash Flow / Share | $-0.45 | · | $-0.31 | $-0.23 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.16 | · | $0.19 | $0.46 | $0.30 | $0.42 | $0.98 | $0.69 | $0.73 | $0.03 | $0.14 | $0.22 | |
| EPS (TTM) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | $257.0K | $0 | · | $0 | $400.0K | $54.0K | $0 | |
| Net Income TTM | $-119M | $-96M | $-55M | $-38M | $-43M | $-50M | $-78M | $-62M | $-30M | $-11M | $-9M | $-29M | |
| Market Cap | $1.23B | · | $649M | $177M | $141M | $62M | $228M | $266M | $453M | · | · | · | |
| Enterprise Value | $1.03B | · | $513M | $77M | $6M | · | · | · | · | · | · | · | |
| P/E | -11.4 | -6.4 | -14.2 | -6.2 | -3.9 | · | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | 242.3 | · | · | · | · | · | · | |
| P/B | 6.1 | · | 4.6 | 1.6 | 1.0 | 1.0 | 2.2 | 2.5 | 3.8 | · | · | · | |
| P / Tangible Book | 6.1 | 3.1 | 4.6 | 1.6 | 1.0 | 1.0 | · | · | · | · | · | · | |
| P / Cash Flow | -12.2 | · | -12.7 | -5.1 | -3.5 | -1.6 | -5.0 | -6.8 | -16.0 | · | · | · | |
| P / FCF | -12.2 | · | -12.6 | -5.1 | -3.5 | -1.6 | -5.0 | -6.7 | -15.8 | · | · | · | |
| EV / EBITDA | -8.3 | · | -8.6 | -2.0 | -0.1 | · | · | · | · | · | · | · | |
| EV / FCF | -10.2 | · | -10.0 | -2.2 | -0.1 | · | · | · | · | · | · | · | |
| Earnings Yield | -8.8% | -15.6% | -7.0% | -16.1% | -25.8% | · | · | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $19M | $16M | $13M | $10M | $11M | $9M | $8M | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $3M | $2M | |
| Operating Expenses | $41M | $39M | $33M | $30M | $31M | $28M | $31M | $26M | $23M | $22M | $18M | $18M | $12M | $12M | $11M | $11M | |
| Operating Income | $-41M | $-39M | $-33M | $-30M | $-31M | $-28M | $-31M | $-26M | $-23M | $-22M | $-18M | $-18M | $-12M | $-12M | $-11M | $-11M | |
| Other Non-op | $737.0K | $2M | $1M | $694.0K | $1M | $2M | $2M | $2M | $947.0K | $2M | $2M | $1M | $778.0K | $2M | $575.0K | $149.0K | |
| Pretax Income | · | · | · | · | · | $-27M | · | · | · | $-20M | · | · | · | · | · | · | |
| Net Income | $-40M | $-37M | $-32M | $-30M | $-30M | $-27M | $-29M | $-24M | $-22M | $-20M | $-16M | $-17M | $-11M | $-11M | $-10M | $-10M | |
| EPS (Basic) | $-0.16 | $-0.15 | $-0.13 | $-0.14 | $-0.14 | $-0.12 | $-0.14 | $-0.11 | $-0.12 | $-0.11 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | |
| EPS (Diluted) | $-0.16 | $-0.15 | $-0.13 | $-0.14 | $-0.14 | $-0.12 | $-0.14 | $-0.11 | $-0.12 | $-0.11 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.07 | $-0.07 | |
| Shares (Basic) | 253,569,891 | 253,280,551 | · | 216,462,161 | 216,431,348 | 216,146,934 | · | 211,847,651 | 182,584,078 | 182,550,109 | · | 174,696,191 | 152,796,617 | 152,781,580 | · | 152,773,015 | |
| Shares (Diluted) | 253,569,891 | 253,280,551 | · | 216,462,161 | 216,431,348 | 216,146,934 | · | 211,847,651 | 182,584,078 | 182,550,109 | · | 174,696,191 | 152,796,617 | 152,781,580 | · | 152,773,015 | |
| EBITDA | $-41M | $-39M | · | $-30M | $-31M | $-28M | · | $-26M | $-23M | $-22M | · | $-18M | $-12M | $-12M | · | $-11M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $42M | $39M | $33M | $16M | $17M | $20M | $15M | $21M | $24M | $17M | $27M | $28M | $23M | $34M | $52M | $120M | |
| Short-term Investments | $131M | $164M | $203M | $108M | $129M | $153M | $181M | $198M | $98M | $126M | $136M | $141M | $82M | $81M | $74M | $14M | |
| Prepaid Expense | $5M | $6M | $6M | $4M | $5M | $5M | $6M | $7M | $6M | $3M | $4M | $2M | $3M | $3M | $3M | $3M | |
| Current Assets | $178M | $209M | $242M | $128M | $151M | $177M | $202M | $226M | $128M | $146M | $166M | $170M | $108M | $118M | $129M | $137M | |
| PP&E (Net) | $641.0K | $130.0K | $100.0K | $85.0K | $119.0K | $138.0K | $165.0K | $206.0K | $236.0K | $248.0K | $270.0K | $277.0K | $264.0K | $47.0K | $51.0K | $59.0K | |
| PP&E (Gross) | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $886.0K | $84.0K | $990.0K | $1M | $1M | $242.0K | $1M | $1M | $1M | $387.0K | $1M | $888.0K | $868.0K | $116.0K | $876.0K | |
| Total Assets | $192M | $222M | $253M | $141M | $164M | $189M | $213M | $239M | $140M | $158M | $178M | $182M | $120M | $129M | $140M | $148M | |
| Accounts Payable | $7M | $4M | $6M | $4M | $5M | $6M | $5M | $5M | $3M | $3M | $4M | $3M | $3M | $2M | $1M | $893.0K | |
| Accrued Liabilities | $11M | $11M | $15M | $13M | $9M | $6M | $10M | $8M | $8M | $7M | $7M | $6M | $3M | $3M | $5M | $4M | |
| Current Liabilities | $18M | $16M | $20M | $17M | $14M | $12M | $15M | $13M | $11M | $10M | $11M | $9M | $6M | $5M | $6M | $5M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | $300.0K | · | · | · | · | |
| Other Non-current Liabilities | $770.0K | · | $0 | $0 | $0 | $44.0K | $87.0K | $128.0K | $169.0K | $208.0K | $247.0K | $284.0K | $20.0K | $37.0K | $54.0K | $71.0K | |
| Total Liabilities | $48M | $46M | $50M | $47M | $43M | $41M | $41M | $39M | $38M | $36M | $37M | $36M | $32M | $31M | $32M | $31M | |
| Long-term Debt | $30M | $30M | $30M | $30M | $30M | $30M | · | $27M | $26M | $26M | · | $26M | $26M | $26M | · | $26M | |
| Total Debt | $30M | $30M | · | $30M | $30M | $30M | · | $27M | $26M | $26M | · | $26M | $26M | $26M | · | $26M | |
| Common Stock | $204.0K | $204.0K | $204.0K | $173.0K | $173.0K | $173.0K | $173.0K | $172.0K | $140.0K | $140.0K | $140.0K | $137.0K | $116.0K | $116.0K | $116.0K | $116.0K | |
| Retained Earnings | $-686M | $-645M | $-608M | $-576M | $-546M | $-516M | $-489M | $-460M | $-436M | $-414M | $-393M | $-377M | $-361M | $-349M | $-339M | $-328M | |
| AOCI | $-534.0K | $-429.0K | $-87.0K | $-155.0K | $-216.0K | $-632.0K | $-750.0K | $299.0K | $-880.0K | $-742.0K | $-271.0K | $-942.0K | $-619.0K | $-461.0K | $-605.0K | $-2M | |
| Stockholders' Equity | $144M | $176M | $203M | $94M | $120M | $148M | $171M | $199M | $102M | $122M | $140M | $147M | $88M | $98M | $108M | $117M | |
| Liabilities + Equity | $192M | $222M | $253M | $141M | $164M | $189M | $213M | $239M | $140M | $158M | $178M | $182M | $120M | $129M | $140M | $148M | |
| Shares Outstanding | 205,399,365 | 204,922,140 | 204,567,283 | 172,850,443 | 172,836,922 | 172,703,390 | 172,423,223 | 170,842,763 | 138,199,047 | 138,176,641 | 138,143,545 | 135,339,836 | 114,150,455 | 114,064,736 | 114,046,345 | 114,042,642 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $28.0K | $24.0K | $-13.0K | $35.0K | $34.0K | $30.0K | $32.0K | $33.0K | $33.0K | $32.0K | $31.0K | $30.0K | $8.0K | $8.0K | $7.0K | $8.0K | |
| Stock-based Comp | $8M | $11M | $5M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $995.0K | $958.0K | $864.0K | $561.0K | $450.0K | |
| Operating Cash Flow | $-30M | $-33M | $-25M | $-23M | $-26M | $-27M | $-23M | $-23M | $-22M | $-21M | $-16M | $-13M | $-10M | $-12M | $-9M | $-8M | |
| CapEx | $222.0K | $54.0K | $2.0K | $2.0K | $15.0K | $3.0K | $-9.0K | $3.0K | $21.0K | $10.0K | $24.0K | $43.0K | $225.0K | $4.0K | $0 | $4.0K | |
| Investing Cash Flow | $33M | $39M | $-94M | $21M | $24M | $29M | $18M | $-98M | $30M | $11M | $7M | $-57M | $-1M | $-6M | $-59M | $33M | |
| Debt Issued | · | · | $0 | $0 | $0 | $30M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $189.0K | $-195.0K | $136M | $-23.0K | $-49.0K | $2M | $-843.0K | $118M | $55.0K | $49.0K | $8M | $75M | $104.0K | $26.0K | $1.0K | $-1.0K | |
| Net Change in Cash | $3M | $6M | $17M | $-1M | $-2M | $4M | $-6M | $-2M | $7M | $-10M | $-1M | $5M | $-11M | $-18M | $-68M | $25M | |
| Free Cash Flow | · | $-33M | · | · | · | $-27M | · | · | · | $-21M | · | · | · | $-12M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -22.6% | -18.1% | · | -15.6% | -20.0% | -15.3% | · | -11.5% | -17.1% | -14.1% | · | -10.1% | -8.3% | -7.1% | · | -6.2% | |
| ROE | -30.5% | -23.0% | · | -20.1% | -27.4% | -19.8% | · | -14.0% | -23.5% | -18.5% | · | -12.6% | -10.7% | -9.0% | · | -7.6% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.1 | 13.5 | · | 7.7 | 11.1 | 14.9 | · | 17.7 | 11.3 | 14.9 | · | 19.0 | 18.3 | 23.9 | · | 26.5 | |
| Quick Ratio | 9.8 | 13.0 | · | 7.4 | 10.7 | 14.5 | · | 17.2 | 10.8 | 14.6 | · | 18.8 | 17.9 | 23.3 | · | 26.0 | |
| Debt / Equity | 0.2 | 0.2 | · | 0.3 | 0.2 | 0.2 | · | 0.1 | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.2 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.3 | 0.2 | 0.2 | · | 0.1 | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.70 | $0.86 | · | $0.55 | $0.70 | $0.86 | · | $1.17 | $0.74 | $0.88 | · | $1.08 | $0.77 | $0.86 | · | $1.02 | |
| Cash Flow / Share | · | $-0.13 | · | · | · | $-0.13 | · | · | · | $-0.11 | · | · | · | $-0.08 | · | · | |
| Cash / Share | $0.20 | $0.19 | · | $0.09 | $0.10 | $0.11 | · | $0.13 | $0.17 | $0.12 | · | $0.20 | $0.20 | $0.30 | · | $1.05 | |
| EPS (TTM) | $-0.58 | $-0.56 | · | $-0.54 | $-0.51 | $-0.49 | · | $-0.43 | $-0.42 | $-0.37 | · | $-0.31 | $-0.28 | $-0.27 | · | $-0.25 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-139M | $-129M | · | $-116M | $-110M | $-102M | · | $-83M | $-75M | $-64M | · | $-49M | $-43M | $-40M | · | $-39M | |
| Market Cap | $1.27B | $1.12B | · | $617M | $394M | $478M | · | $724M | $557M | $688M | · | $512M | $365M | $222M | · | $177M | |
| Enterprise Value | $1.12B | $946M | · | $522M | $277M | $335M | · | $531M | $462M | $571M | · | $370M | $286M | $134M | · | $69M | |
| P/E | -10.6 | -9.8 | · | -6.6 | -4.5 | -5.7 | · | -9.9 | -9.6 | -13.5 | · | -12.2 | -11.4 | -7.2 | · | -6.2 | |
| P/B | 8.8 | 6.4 | · | 6.5 | 3.3 | 3.2 | · | 3.6 | 5.5 | 5.6 | · | 3.5 | 4.2 | 2.3 | · | 1.5 | |
| P / Tangible Book | 8.8 | 6.4 | · | 6.5 | 3.3 | 3.2 | · | 3.6 | 5.5 | 5.6 | · | 3.5 | 4.2 | 2.3 | · | 1.5 | |
| P / Cash Flow | · | -33.9 | · | · | · | -17.6 | · | · | · | -33.3 | · | · | · | -18.5 | · | · | |
| Earnings Yield | -9.4% | -10.3% | · | -15.1% | -22.4% | -17.7% | · | -10.1% | -10.4% | -7.4% | · | -8.2% | -8.8% | -13.9% | · | -16.1% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Gelir | $-119M | $-96M | $-55M | $-38M | $-43M |
| Seyreltilmiş Hisse Başı Kâr | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.1 | · | 0.2 | 0.2 | 0.2 |
| Cari Oran | 11.8 | · | 15.7 | 22.0 | 11.3 |
| Cari Oran | 11.6 | · | 15.3 | 21.5 | 11.0 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-101M | · | $-51M | $-35M | $-40M |
Kurumsal Sahipler (13F) 194 dosya · $1.4B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
194
Tutulan Değer
$1.4B
Yeni pozisyonlar
23
Çıkan pozisyonlar
25
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 23 (-39 önceki Ç'ye göre) | 25 (+6 önceki Ç'ye göre) | 72 (+5 önceki Ç'ye göre) | 58 (+21 önceki Ç'ye göre) | +4.1M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| NEA Management Company, LLC | $150.742.986 | 24.471.264 | 10,78% | Hisse senetleri |
| Bain Capital Life Sciences Investors, LLC | $108.419.826 | 17.600.621 | 7,75% | Hisse senetleri |
| Venrock Adviser, LLC | $90.835.009 | 14.745.943 | 6,50% | Hisse senetleri |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $83.585.040 | 13.569.000 | 5,98% | Hisse senetleri |
| BlackRock, Inc. | $76.966.107 | 12.494.498 | 5,50% | Hisse senetleri |
| TCG Crossover Management, LLC | $76.151.183 | 12.362.205 | 5,45% | Hisse senetleri |
| VANGUARD GROUP INC | $60.551.132 | 10.041.647 | 4,33% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $59.880.448 | 9.720.852 | 4,28% | Hisse senetleri |
| Polar Capital Holdings Plc | $58.777.402 | 9.541.786 | 4,20% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $48.864.477 | 7.932.545 | 3,49% | Hisse senetleri |
| Nantahala Capital Management, LLC | $42.977.150 | 6.976.810 | 3,07% | Hisse senetleri |
| STATE STREET CORP | $40.368.624 | 6.553.348 | 2,89% | Hisse senetleri |
| MARSHALL WACE, LLP | $38.543.053 | 6.256.989 | 2,76% | Hisse senetleri |
| RTW INVESTMENTS, LP | $36.666.661 | 5.952.380 | 2,62% | Hisse senetleri |
| Woodline Partners LP | $26.149.933 | 4.245.119 | 1,87% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $24.392.984 | 3.959.900 | 1,74% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $23.857.705 | 3.872.133 | 1,71% | Hisse senetleri |
| Spruce Street Capital LP | $21.267.868 | 3.452.576 | 1,52% | Hisse senetleri |
| Rosalind Advisors, Inc. | $19.577.225 | 3.178.121 | 1,40% | Hisse senetleri |
| EMERALD ADVISERS, LLC | $19.394.384 | 3.148.439 | 1,39% | Hisse senetleri |
| Pictet Asset Management Holding SA | $17.020.419 | 2.763.055 | 1,22% | Hisse senetleri |
| Vestal Point Capital, LP | $16.755.200 | 2.720.000 | 1,20% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $16.600.042 | 2.694.812 | 1,19% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $15.492.388 | 2.514.998 | 1,11% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $15.474.862 | 2.512.153 | 1,11% | Hisse senetleri |
| EMERALD MUTUAL FUND ADVISERS TRUST | $14.636.154 | 2.375.999 | 1,05% | Hisse senetleri |
| NAN FUNG TRINITY (HK) LTD | $11.348.876 | 1.842.350 | 0,81% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $10.076.762 | 1.635.838 | 0,72% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $8.644.999 | 1.403.409 | 0,62% | Hisse senetleri |
| SILVERARC CAPITAL MANAGEMENT, LLC | $8.349.627 | 1.355.459 | 0,60% | Hisse senetleri |
| ALGERT GLOBAL LLC | $8.188.235 | 1.329.259 | 0,59% | Hisse senetleri |
| NORTHERN TRUST CORP | $8.025.894 | 1.302.905 | 0,57% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $7.211.802 | 1.170.747 | 0,52% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $6.412.597 | 1.041.006 | 0,46% | Hisse senetleri |
| Longaeva Partners L.P. | $6.257.864 | 1.015.887 | 0,45% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $6.219.696 | 1.009.691 | 0,44% | Hisse senetleri |
| SUPERSTRING CAPITAL MANAGEMENT LP | $6.021.154 | 977.460 | 0,43% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $5.328.129 | 864.956 | 0,38% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $5.108.767 | 829.345 | 0,37% | Hisse senetleri |
| SPHERA FUNDS MANAGEMENT LTD. | $4.657.970 | 756.164 | 0,33% | Hisse senetleri |
| Swedbank AB | $4.409.944 | 715.900 | 0,32% | Hisse senetleri |
| VOYA INVESTMENT MANAGEMENT LLC | $4.264.020 | 692.211 | 0,30% | Hisse senetleri |
| F/m Investments LLC | $4.055.461 | 658.354 | 0,29% | Hisse senetleri |
| Sio Capital Management, LLC | $3.804.878 | 617.675 | 0,27% | Hisse senetleri |
| AXA Investment Managers S.A. | $3.760.142 | 1.053.261 | 0,27% | Hisse senetleri |
| KVP Capital Advisors, LP | $3.728.525 | 605.280 | 0,27% | Hisse senetleri |
| Integral Health Asset Management, LLC | $3.696.000 | 600.000 | 0,26% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $3.205.393 | 520.356 | 0,23% | Hisse senetleri |
| UBS Group AG | $3.160.240 | 513.026 | 0,23% | Hisse senetleri |
| Moody Aldrich Partners LLC | $2.974.005 | 482.793 | 0,21% | Hisse senetleri |
Aktivistler ve %5+ sahipler 7 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Growth Equity Opportunities 17, LLC, New Enterprise Associates 17, L.P., NEA Partners 17, L.P., NEA 17 GP, LLC, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Edward T. Mathers, Scott D. Sandell, Paul Walker, Rick Yang ×4 başvurular | 14 Kasım 2025 | 12,00% | Değişiklik | Pasif yatırım | SEC |
| Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP ×5 başvurular | 27 Mart 2025 | 9,99% | Değişiklik | · | SEC |
| High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., Carl C. Icahn | 30 Aralık 2015 | · | İlk başvuru | · | SEC |
| Evan M. Levine, Mark Capital, LLC | 06 Şubat 2009 | · | İlk başvuru | · | SEC |
| Evan Levine, Mark Capital, LLC ×2 başvurular | 19 Aralık 2007 | · | İlk başvuru | · | SEC |
| Matthew Balk ×2 başvurular | 01 Haziran 2006 | · | İlk başvuru | Pasif yatırım | SEC |
| High River Limited Partnership S.S. OR, Hopper Investments LLC S.S. OR, Barberry Corp. S.S. OR, Icahn Partners Master Fund LP S.S. OR, Icahn Offshore LP S.S. OR, CCI Offshore Corp. S.S. OR, Icahn Partners LP S.S. OR, Icahn Onshore LP S.S. OR, CCI Onshore Corp. S.S. OR, Carl C. Icahn S.S. OR | 05 Ağustos 2005 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 59 içeriden öğrenenler · 31 yöneticiler · 25 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Matthew Pauls | CHIEF EXECUTIVE OFFICER | 16 Aralık 2025 G | 1.188.050 | 0 | 0 | $0 |
| Robert N Neville | Chief Executive Officer | 20 Aralık 2019 A | 498.028 | 0 | 0 | $0 |
| Brian M Culley | CEO and Director | 20 Ocak 2017 A | 34.500 | 0 | 0 | $0 |
| Evan Levine | CEO & President | 08 Şubat 2008 P | 4.395.000 | 0 | 0 | $0 |
| Nicholas J Virca | CEO and President | 15 Aralık 2003 X | 347.956 | 0 | 0 | $0 |
| David L Lowrance | Chief Financial Officer | 22 Haziran 2026 M | 536.032 | 0 | 1 | $-2.240.919 |
| Brandi Roberts | Chief Financial Officer & SVP | 20 Ocak 2017 A | 38.000 | 0 | 0 | $0 |
| Mark Bagnall | CFO & Executive Vice President | 03 Nisan 2008 A | · | 0 | 0 | $0 |
| Gregory P Hanson | Senior VP, CFO & Treasurer | 20 Aralık 2006 A | · | 0 | 0 | $0 |
| Carrie Carlander | CFO, Treas, Secy, VP Finance | 31 Ocak 2006 A | 25.000 | 0 | 0 | $0 |
| Jaakko Taneli Jouhikainen | President and Chief Operating Officer | 20 Aralık 2019 A | 167.569 | 0 | 0 | $0 |
| Patrick L Keran | President & COO | 02 Ocak 2015 A | · | 0 | 0 | $0 |
| James A Merritt | President & Chf Med Officer | 14 Aralık 2007 P | 35.000 | 0 | 0 | $0 |
| Braden C. Parker | Chief Commercial Officer | 24 Eylül 2026 F | 75.677 | 0 | 0 | $0 |
| Robert Matthew Lutz | Chief Fin. & Operating Officer | 15 Temmuz 2026 A | 328.977 | 0 | 0 | $0 |
| Kathleen R. Mccabe | Chief Legal Officer | 14 Aralık 2025 F | 519.232 | 0 | 0 | $0 |
| Anne Erickson | Chief Business Officer | 14 Aralık 2025 F | 371.712 | 0 | 0 | $0 |
| Yasmine Wasfi | Chief Medical Officer | 04 Aralık 2025 F | 168.008 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Medical Officer | 12 Aralık 2024 A | 340.050 | 0 | 0 | $0 |
| Badrul A. Chowdhury | CHIEF MEDICAL OFFICER | 14 Aralık 2021 A | 300.000 | 0 | 0 | $0 |
| Shana Hood | General Counsel & VP | 20 Ocak 2017 A | · | 0 | 0 | $0 |
| Edwin L. Parsley | Chief Medical Officer & SVP | 20 Ocak 2017 A | · | 0 | 0 | $0 |
| Gregory D. Gorgas | Senior VP, Commercial | 04 Ocak 2016 A | · | 0 | 0 | $0 |
| Robert Martin Emanuele | Senior VP, Development | 04 Ocak 2016 A | 294.598 | 0 | 0 | $0 |
| Santosh Vetticaden | Chief Medical Officer & SVP | 19 Haziran 2014 A | · | 0 | 0 | $0 |
| Mark E. Erwin | SVP, Operations | 30 Ocak 2009 A | · | 0 | 0 | $0 |
| Michele Yelmene | VP, Regulatory & QA | 30 Ocak 2009 A | · | 0 | 0 | $0 |
| Joan M Robbins | CSO, Sr. VP | 14 Mayıs 2008 P | 10.000 | 0 | 0 | $0 |
| Joachim Ph Schupp | VP, Medical Affairs | 31 Mart 2008 A | · | 0 | 0 | $0 |
| Mark Joseph Cantwell | VP, Research & Development | 12 Ocak 2007 A | · | 0 | 0 | $0 |
| Cellia Habita | Senior VP, Clinical & Medical | 07 Ekim 2004 P | 5.000 | 0 | 0 | $0 |
| Joseph S Mccracken | Yönetim kurulu üyesi | 16 Şubat 2026 M | 302.644 | 0 | 0 | $0 |
| David A Ramsay | Yönetim kurulu üyesi | 19 Aralık 2025 S | 2.533.642 | 0 | 1 | $-121.200 |
| An Van Es-Johansson | Yönetim kurulu üyesi | 09 Aralık 2025 A | 102.500 | 0 | 0 | $0 |
| Nevan C Elam | Yönetim kurulu üyesi | 09 Aralık 2025 A | 106.887 | 0 | 0 | $0 |
| Richard J Hawkins | Yönetim kurulu üyesi | 09 Aralık 2025 A | 161.326 | 0 | 0 | $0 |
| Ricky Sun | Yönetim kurulu üyesi | 14 Aralık 2023 A | 22.500 | 0 | 0 | $0 |
| Yuri Pikover | Yönetim kurulu üyesi | 13 Aralık 2018 A | 153.734 | 0 | 0 | $0 |
| Peter Greenleaf | Yönetim kurulu üyesi | 20 Ocak 2017 A | · | 0 | 0 | $0 |
| DITTRICH HOWARD | Yönetim kurulu üyesi | 20 Ocak 2017 A | · | 0 | 0 | $0 |
| Lewis Shuster | Yönetim kurulu üyesi | 11 Haziran 2015 A | · | 0 | 0 | $0 |
| Jack Lief | Yönetim kurulu üyesi | 11 Haziran 2015 A | · | 0 | 0 | $0 |
| Ted W Love | Yönetim kurulu üyesi | 19 Haziran 2013 A | · | 0 | 0 | $0 |
| Odysseas D Kostas | Yönetim kurulu üyesi | 30 Haziran 2010 A | · | 0 | 0 | $0 |
| Eric K Rowinsky | Yönetim kurulu üyesi | 30 Haziran 2010 A | · | 0 | 0 | $0 |
| Mark Jerome Pykett | Yönetim kurulu üyesi | 30 Haziran 2010 A | 8.000 | 0 | 0 | $0 |
| Michael M Goldberg | Yönetim kurulu üyesi | 30 Haziran 2010 A | 26.000 | 0 | 0 | $0 |
| DENNER ALEXANDER J | Yönetim kurulu üyesi | 30 Haziran 2008 A | · | 0 | 0 | $0 |
| Ross M Johnson | Yönetim kurulu üyesi | 21 Aralık 2006 X | 1.621.779 | 0 | 0 | $0 |
| Meister, Keith A. | Yönetim kurulu üyesi | 02 Haziran 2006 A | · | 0 | 0 | $0 |
| Rick Yang | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Carmen Chang | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Mohamad Makhzoumi | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Ali Behbahani | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Anthony A. Florence, Jr. | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Paul Walker | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Edward T. Mathers | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Forest Baskett | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
| Scott D. Sandell | 10% sahip | 17 Temmuz 2023 P | 24.471.264 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 27 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,70% | 59.090 NS | 31 Temmuz 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 409.369 NS | 31 Temmuz 2026 | N-PORT |
| IWC · iShares Trust | 0,19% | 520.275 SH | 11 Eylül 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,12% | 108.602 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,09% | 301.950 SH | 19 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,07% | 14.661 SH | 01 Ekim 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,06% | 163.980 SH | 19 Ağustos 2026 | Günlük |
| IWO · iShares Trust | 0,05% | 1.436.801 SH | 11 Eylül 2026 | Günlük |
| IBB · iShares Trust | 0,04% | 822.223 SH | 11 Eylül 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,03% | 1.484 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,03% | 880.662 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,03% | 73.241 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 3.929.899 SH | 11 Eylül 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 105.882 SH | 01 Ekim 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1.567.813 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 277.850 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 43.814 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,01% | 12.952 SH | 10 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 19.118 NS | 31 Temmuz 2026 | N-PORT |
| WSML · iShares Trust | 0,00% | 5.664 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 43.112 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 170.809 SH | 11 Eylül 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,00% | 23.796 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 6.164.961 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 11.396 SH | 19 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 4.332 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 11.041 SH | 11 Eylül 2026 | Günlük |
SVRA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 14 analist
AL
Medyan hedef
$10.25
+113,1%
5 35,7%
Güçlü Al
8 57,1%
Al
1 7,1%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
8 analist · 2026-09-28Ortalama hedef $10.94 +127,4%
← Tüm hedeflerin altında
Mevcut fiyat $4.81
Düşük$9.00
Ortalama$10.94
Yüksek$16.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| SVRA | $1.23B | -11.4 | · | · | -73.4% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
| AKTS | · | · | · | · | · | · |
| CGEM | $624M | -3.2 | · | · | -44.0% | · |
| ODTX | · | · | · | · | · | · |
| KURA | $913M | -3.3 | 25.2% | -413.0% | -116.2% | · |
| CRVS | $575M | -14.5 | · | · | -21.6% | · |
| JBIO | $761M | -4.8 | · | · | -47.7% | · |
| GLUE | $1.03B | · | 63.5% | -31.2% | -15.4% | · |
| RIGL | $784M | 2.2 | 64.1% | 124.7% | 155.1% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 11, 2026